Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.

Google Ventures-backed Iterative will now expand its platform into burgeoning therapeutic areas like cardiology and obesity.

After two years, there was an 87% reduction in death in ALS patients treated with Corcept's dazucorilant compared with those who received placebo.

Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 to treat moderate-to-severe atopic dermatitis.

Merck KGaA has dosed the first patient in its Phase III clinical programme, evaluating enpatoran in individuals with lupus who have active skin manifestations.

Newleos Therapeutics has dosed the first participant in its Phase Ib clinical study evaluating NTX-2001, a partial agonist of TAAR1, for AUD.

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed benefit as a second-line therapy in a Phase III ...

Ahead of Biomed Israel, Ittai Harel highlights a growing cohort of companies leveraging AI and data science tools to revolutionise clinical research.

An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned in schizophrenia.

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Male infertility remains difficult to treat, especially as most fertility treatments such as IVF, prioritise treatment of the female partner.

While the drug has not been investigated in a head-to-head weight loss trial, data suggest that Lilly's Zepbound is more effective than Boehringer's survodutide.